This article is intended for research and educational purposes only. KPV and all peptides discussed herein are sold exclusively as research chemicals and are not intended for human or animal use.
Introduction: The C-Terminal Fragment of α-MSH
Alpha-melanocyte-stimulating hormone (α-MSH) is a tridecapeptide derived from proopiomelanocortin (POMC) that has long been recognized as a potent modulator of inflammatory signaling cascades. Among its structural derivatives, the C-terminal tripeptide KPV (Lys11-Pro12-Val13, corresponding to positions 11–13 of α-MSH) has emerged as a particularly compelling subject of investigation. Despite its minimal molecular weight of approximately 342 Da, KPV retains much of the parent hormone’s anti-inflammatory potency while exhibiting distinct mechanistic properties that do not depend on classical melanocortin receptor activation (Getting et al., 2003; Luger & Brzoska, 2007).
Since its initial characterization, KPV has been studied extensively in cell culture systems and preclinical inflammatory models. Its primary mechanism of action centers on the inhibition of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway—a master transcriptional regulator of pro-inflammatory cytokine production. This review synthesizes current evidence on KPV’s molecular interactions with NF-κB pathway components, its cellular uptake via the peptide transporter PepT1 (SLC15A1), and recent advances in delivery platforms that have expanded the scope of KPV research.
Molecular Mechanism: KPV and NF-κB Signaling Inhibition
Competitive Inhibition of p65/RelA Nuclear Import
The canonical NF-κB signaling cascade involves the phosphorylation and proteasomal degradation of the inhibitory protein IκBα, which normally sequesters the p65/RelA subunit in the cytoplasm. Upon IκBα degradation, p65/RelA translocates to the nucleus via importin-α (Imp-α) transport machinery, where it drives transcription of pro-inflammatory genes including TNF-α, IL-1β, IL-6, and IL-8.
Land (2012) demonstrated that KPV operates through a mechanism distinct from upstream IKK kinase inhibition. In human bronchial epithelial cells stimulated with TNF-α, KPV treatment resulted in a statistically significant increase in total IκBα abundance; however, the ratio of IKK-phosphorylated IκBα to total IκBα remained unchanged. This critical observation indicated that KPV does not prevent IκBα phosphorylation per se, but rather stabilizes IκBα pools through a downstream mechanism.
Immunofluorescence analysis revealed that KPV abolished TNF-α–evoked nuclear import of p65/RelA. Competition binding assays demonstrated a direct interaction between KPV and the Imp-α3 binding site on p65/RelA, specifically involving blockade of the importin-α armadillo domains 7 and 8. Pepsite binding analysis of KPV interaction with the closely related isoform Imp-α2 confirmed multiple possible interactions involving two or more KPV residues with amino acids 360–403, spanning armadillo repeat arms 7 and 8 (Land, 2012). This competitive inhibition of the nuclear localization signal (NLS)–importin interface represents a mechanistically novel approach to NF-κB suppression that is independent of melanocortin receptors MC1R–MC5R.
Downstream Cytokine Suppression
By preventing p65/RelA nuclear translocation, KPV effectively attenuates transcription of the NF-κB–dependent pro-inflammatory gene cassette. In in vitro models, nanomolar concentrations of KPV reduce secretion of TNF-α, IL-1β, IL-6, and IL-8 from stimulated epithelial and immune cell lines (Dalmasso et al., 2008). The functional consequence is a broad dampening of the inflammatory response at the transcriptional level, without the immunosuppressive liabilities associated with global IKK or proteasome inhibition.
PepT1-Mediated Cellular Uptake: The SLC15A1 Transporter Axis
A defining feature of KPV pharmacology is its transport across epithelial membranes via the proton-coupled oligopeptide transporter PepT1 (SLC15A1). PepT1 normally mediates concentrative uptake of dietary di- and tripeptides in the small intestine, coupling substrate translocation to the inwardly directed transmembrane electrochemical proton gradient. Cryo-electron microscopy studies have resolved the molecular architecture of human PepT1 in multiple conformational states, revealing the structural basis for its remarkable substrate promiscuity (Killer et al., 2021).
Dalmasso et al. (2008) provided the foundational evidence that PepT1 transports KPV into intestinal epithelial cells and that the subsequent increase in intracellular KPV concentration decreases activation of both NF-κB and MAPK inflammatory signaling pathways, ultimately reducing IL-8 secretion. Crucially, PepT1 expression is upregulated in colonic epithelium during inflammatory states, creating a pathophysiologically relevant uptake mechanism: inflamed tissue exhibits enhanced capacity for KPV absorption even at low extracellular concentrations (Dalmasso et al., 2008).
This transporter-mediated mechanism has significant implications for research into targeted delivery, as KPV’s tripeptide structure makes it an ideal substrate for SLC15A1-dependent cellular entry—a property not shared by larger melanocortin peptides or full-length α-MSH.
KPV in Preclinical Inflammatory Models
Intestinal Inflammation and Colitis Models
Kannengiesser et al. (2008) evaluated KPV in murine models of inflammatory bowel disease using both dextran sodium sulfate (DSS)– and 2,4,6-trinitrobenzenesulfonic acid (TNBS)–induced colitis. Oral administration of KPV reduced loss of body weight, colonic myeloperoxidase (MPO) activity, and histological signs of inflammation, while markedly decreasing pro-inflammatory cytokine mRNA levels. These findings established that the NF-κB inhibitory activity observed in vitro translates to measurable anti-inflammatory efficacy in preclinical intestinal models.
This product is sold for research purposes only and is not intended for human or animal consumption.
Airway Epithelial Cell Models
In human bronchial epithelial cells (16HBE14o- cell line), KPV suppressed both TNF-α– and LPS-induced NF-κB activation at concentrations as low as 10-9 M. The compound also reduced IL-8 secretion and suppressed systemic inflammation cues including COX-2 and ICAM-1 expression (Land, 2012). These data extend the anti-inflammatory profile of KPV beyond the gastrointestinal tract to respiratory epithelial surfaces, broadening the scope of potential research applications.
Keratinocyte and Dermal Models
Elliott et al. (2004) demonstrated that KPV activates signaling pathways in human keratinocytes, suggesting a direct mechanism for modulating cutaneous inflammatory responses. More recently, Sung et al. (2025) investigated KPV’s protective effects against fine particulate matter (PM10)–induced damage in HaCaT keratinocytes. Treatment with KPV restored cell viability, reduced IL-1β secretion, and inhibited reactive oxygen species (ROS) production. Mechanistically, KPV attenuated activation of the ERK/p38 MAPK axis and suppressed NF-κB–dependent expression of apoptosis-related proteins (Bax, Bcl-2, cleaved caspase-3), demonstrating dual anti-inflammatory and anti-apoptotic activity in cutaneous cell models.
Advanced Delivery Platforms: Nanoparticle and Hydrogel Systems
Hyaluronic Acid–Functionalized Nanoparticles
Xiao et al. (2017) developed hyaluronic acid (HA)–functionalized polymeric nanoparticles for targeted oral delivery of KPV. The HA-KPV nanoparticles (approximately 272 nm diameter, zeta potential of −5.3 mV) successfully mediated targeted delivery to colonic epithelial cells and macrophages. A critical finding was that HA-KPV nanoparticles achieved therapeutic efficacy at a dose 1,200-fold lower than free KPV in solution, underscoring the potential of nanoparticle-mediated delivery to enhance peptide bioavailability at inflammatory sites.
PepT1-Targeted Co-Assembly Nanodrugs
Zhang et al. (2024) reported a PepT1-targeted nanodrug platform based on co-assembly of KPV with the immunosuppressant FK506 (tacrolimus). These nanoparticles accumulated selectively in diseased intestinal regions by recognizing aberrantly expressed PepT1. In DSS-induced colitis models, treatment reduced oxidative stress markers (MPO, NO, ROS) and pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), while enhancing epithelial barrier integrity through upregulation of Mucin-2, ZO-1, and Claudin-5 expression.
Mucoadhesive Hydrogel Systems
Shao et al. (2021) developed an in situ mucoadhesive hydrogel capturing KPV (KPV@PPP_E) for application in oral mucosal models. The hydrogel formulation demonstrated anti-inflammatory, antibacterial, and tissue-repairing properties, significantly inhibiting IL-1β and TNF-α while upregulating IL-10. Notably, the KPV-loaded hydrogel exhibited antibacterial activity against MRSA-infected gingival ulcer wounds, indicating that KPV’s anti-inflammatory mechanism may synergize with antimicrobial tissue environments.
Self-Immolative Conjugates for Inflammation-Targeted Release
Cheng et al. (2026) introduced a self-immolative peptide prodrug conjugate (SIPPC) platform for oral delivery of anti-inflammatory peptides including KPV. The ROS-responsive conjugate (proKPV) achieved 3.8-fold greater colonic accumulation than free KPV, with enhanced efficacy at a 20-fold lower dose in colitis models. This inflammation-triggered release strategy represents the current frontier in KPV delivery research.
Combination Nanoparticle Platforms
Marotti et al. (2023) developed hybrid lipid nanoparticles functionalized with hyaluronan-KPV conjugates and loaded with teduglutide, creating a combined mucosal healing and immunomodulation platform. This triple-action system promoted endogenous GLP-2 production, provided targeted anti-inflammatory action via CD44/TLR4 pathway modulation, and enabled redox-responsive release of KPV through disulfide bond cleavage.
Melanocortin Receptor Selectivity and Structure-Activity Relationships
While KPV’s anti-inflammatory mechanism operates independently of classical melanocortin receptor activation, recent structure-activity studies have revealed that the –KPV motif plays a pivotal role in modulating melanotropin receptor selectivity. Nyberg et al. (2025) systematically examined the impact of the C-terminal –Lys-Pro-Val sequence on melanotropin conformation and receptor binding, demonstrating that incorporation of the –KPV motif enhanced binding affinity toward melanocortin receptors and modulated receptor preference among the MC1R–MC5R subtypes. These findings provide a structural framework for understanding how the same tripeptide sequence can mediate both receptor-dependent and receptor-independent biological activities—a dual functionality that distinguishes KPV from other melanocortin fragments and positions it as a versatile research tool in peptide pharmacology.
Researchers investigating related melanocortin peptides may find these structure-activity relationships informative for comparative studies. Additional peptides with complementary anti-inflammatory profiles, such as BPC-157 and Thymosin Alpha 1, have also been subjects of active investigation in NF-κB–related signaling research. All peptide research materials used in published studies should be accompanied by verified certificates of analysis.
KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment corresponding to positions 11–13 of alpha-melanocyte-stimulating hormone (α-MSH). Despite comprising only three amino acids with a molecular weight of approximately 342 Da, KPV retains significant anti-inflammatory activity from the parent hormone. Importantly, research demonstrates that KPV’s anti-inflammatory mechanism operates independently of classical melanocortin receptor (MC1R–MC5R) activation, distinguishing it from the full-length α-MSH peptide (Getting et al., 2003; Luger et al., 2003).
How does KPV inhibit the NF-κB signaling pathway?
KPV inhibits NF-κB through competitive blockade of p65/RelA nuclear import. Rather than preventing upstream IκBα phosphorylation, KPV enters the nucleus and competes with p65/RelA for binding to importin-α3 (Imp-α3), specifically at armadillo repeat domains 7 and 8. This prevents nuclear translocation of p65/RelA, thereby suppressing transcription of NF-κB–dependent pro-inflammatory genes including TNF-α, IL-1β, IL-6, and IL-8 (Land, 2012).
What role does PepT1 play in KPV uptake?
PepT1 (SLC15A1) is a proton-coupled oligopeptide transporter that mediates the active cellular uptake of KPV. As a tripeptide, KPV is an optimal substrate for PepT1-mediated transport. PepT1 expression is upregulated during intestinal inflammation, which increases the capacity for KPV absorption in inflamed tissue even at low concentrations. This transporter-mediated mechanism has been leveraged in the design of PepT1-targeted nanoparticle delivery systems (Dalmasso et al., 2008; Zhang et al., 2024).
What cytokines does KPV suppress in cell culture experiments?
In cell culture systems, nanomolar concentrations of KPV have been shown to suppress secretion of TNF-α, IL-1β, IL-6, and IL-8 from stimulated epithelial and immune cells. KPV also reduces expression of COX-2 and ICAM-1 in bronchial epithelial cell models, and attenuates ROS-dependent activation of ERK and p38 MAPK pathways in keratinocyte cultures (Land, 2012; Sung et al., 2025).
How do nanoparticle delivery systems enhance KPV activity?
Hyaluronic acid–functionalized nanoparticles have demonstrated the ability to deliver KPV at effective concentrations 1,200-fold lower than free KPV in solution. More recent self-immolative conjugate systems achieve 3.8-fold greater colonic tissue accumulation through ROS-responsive release mechanisms that are triggered specifically at sites of inflammation. PepT1-targeted co-assembly nanoparticles additionally exploit the upregulated transporter expression in inflamed tissue for enhanced selectivity (Xiao et al., 2017; Cheng et al., 2026).
Does KPV interact with melanocortin receptors?
Structure-activity relationship studies show that the –KPV motif modulates melanotropin receptor selectivity and enhances binding affinity toward melanocortin receptors when incorporated into larger peptide constructs. However, KPV’s anti-inflammatory activity in isolation appears to be primarily mediated through direct NF-κB pathway inhibition rather than classical melanocortin receptor signaling, representing a receptor-independent mechanism (Getting et al., 2003; Nyberg et al., 2025).
What are the most widely studied delivery platforms for KPV research?
Current KPV delivery research encompasses four major platform categories: (1) hyaluronic acid–functionalized polymeric nanoparticles for targeted colonic delivery; (2) PepT1-targeted co-assembly nanodrugs combining KPV with immunosuppressants; (3) mucoadhesive hydrogel systems for topical mucosal application; and (4) inflammation-triggered self-immolative prodrug conjugates for site-specific release. Each platform exploits different aspects of KPV’s physicochemical properties and the pathophysiology of inflammatory tissue environments.
All products referenced in this article are intended for laboratory research purposes only and are not for human or animal use. Researchers should consult institutional review protocols and applicable regulations before initiating any experimental procedures.
References
Cheng J, Wu P, Li C, et al. Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers. Science Advances. 2026;12(3):eaea2989. PubMed
Elliott RJ, Szabo M, Wagner MJ, Kemp EH, MacNeil S, Haycock JW. Alpha-melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. Journal of Investigative Dermatology. 2004;122(4):1010-1019. PubMed
Getting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. Journal of Pharmacology and Experimental Therapeutics. 2003;306(2):631-637. PubMed
Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. 2008;14(3):324-331. PubMed
Killer M, Wald J, Pieprzyk J, Marlovits TC, Löw C. Structural snapshots of human PepT1 and PepT2 reveal mechanistic insights into substrate and drug transport across epithelial membranes. Science Advances. 2021;7(45):eabk3259. PubMed
Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. International Journal of Physiology, Pathophysiology and Pharmacology. 2012;4(2):59-73. PubMed
Luger TA, Brzoska T. α-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Annals of the Rheumatic Diseases. 2007;66(Suppl 3):iii52-iii55. PubMed
Luger TA, Scholzen TE, Brzoska T, Böhm M. New insights into the functions of alpha-MSH and related peptides in the immune system. Annals of the New York Academy of Sciences. 2003;994:133-140. PubMed
Marotti V, Xu Y, Bohns Michalowski C, et al. A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment. Bioactive Materials. 2024;32:206-221. PubMed
Nyberg JB, De la Peña AD, Bao J, Hruby VJ, Cai M. C-terminal tripeptide KPV of α-MSH modulates the selectivity of melanotropins in the melanocortin system. Australian Journal of Chemistry. 2025;78(12). doi:10.1071/CH25144
Shao W, Chen R, Lin G, et al. In situ mucoadhesive hydrogel capturing tripeptide KPV: the anti-inflammatory, antibacterial and repairing effect on chemotherapy-induced oral mucositis. Biomaterials Science. 2022;10(1):227-242. PubMed
Sung J, Ju SY, Park SH, Jung WK, Je JY, Lee SJ. Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway. Tissue and Cell. 2025;95:102837. ScienceDirect
Xiao B, Xu Z, Viennois E, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Molecular Therapy. 2017;25(7):1628-1640. PubMed
Zhang D, Jiang L, Yu F, et al. PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combined treatment of acute and chronic DSS-induced colitis. Frontiers in Pharmacology. 2024;15:1442876. PubMed
Adnan SB, Maarof M, Fauzi MHB, Fadilah NIM. Exploring the role of tripeptides in wound healing and skin regeneration: a comprehensive review. International Journal of Medical Sciences. 2025;22(16):4175-4200. PubMed
Discover how GHRH uses gentle pulses to stimulate your pituitary gland, enhancing anti-aging benefits and supporting deep, restorative sleep. By optimizing your body composition and promoting natural cellular repair, GHRH could be your key to feeling youthful and energized every day.
If you’re curious about buying peptides without a prescription, you’re not alone. The peptide market has exploded in recent years, and understanding what’s legal, what’s safe, and what’s actually available over the counter can be confusing. Here’s the straight answer: Some peptides are available over the counter, but they’re limited to specific types. According to …
Explore AI peptides and how artificial intelligence is revolutionizing drug discovery. Learn about the best solutions in peptide research and development.
KPV Tripeptide and NF-κB Inhibition: Anti-Inflammatory Mechanisms in Cell Culture and Preclinical Models
This article is intended for research and educational purposes only. KPV and all peptides discussed herein are sold exclusively as research chemicals and are not intended for human or animal use.
Introduction: The C-Terminal Fragment of α-MSH
Alpha-melanocyte-stimulating hormone (α-MSH) is a tridecapeptide derived from proopiomelanocortin (POMC) that has long been recognized as a potent modulator of inflammatory signaling cascades. Among its structural derivatives, the C-terminal tripeptide KPV (Lys11-Pro12-Val13, corresponding to positions 11–13 of α-MSH) has emerged as a particularly compelling subject of investigation. Despite its minimal molecular weight of approximately 342 Da, KPV retains much of the parent hormone’s anti-inflammatory potency while exhibiting distinct mechanistic properties that do not depend on classical melanocortin receptor activation (Getting et al., 2003; Luger & Brzoska, 2007).
Since its initial characterization, KPV has been studied extensively in cell culture systems and preclinical inflammatory models. Its primary mechanism of action centers on the inhibition of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway—a master transcriptional regulator of pro-inflammatory cytokine production. This review synthesizes current evidence on KPV’s molecular interactions with NF-κB pathway components, its cellular uptake via the peptide transporter PepT1 (SLC15A1), and recent advances in delivery platforms that have expanded the scope of KPV research.
Molecular Mechanism: KPV and NF-κB Signaling Inhibition
Competitive Inhibition of p65/RelA Nuclear Import
The canonical NF-κB signaling cascade involves the phosphorylation and proteasomal degradation of the inhibitory protein IκBα, which normally sequesters the p65/RelA subunit in the cytoplasm. Upon IκBα degradation, p65/RelA translocates to the nucleus via importin-α (Imp-α) transport machinery, where it drives transcription of pro-inflammatory genes including TNF-α, IL-1β, IL-6, and IL-8.
Land (2012) demonstrated that KPV operates through a mechanism distinct from upstream IKK kinase inhibition. In human bronchial epithelial cells stimulated with TNF-α, KPV treatment resulted in a statistically significant increase in total IκBα abundance; however, the ratio of IKK-phosphorylated IκBα to total IκBα remained unchanged. This critical observation indicated that KPV does not prevent IκBα phosphorylation per se, but rather stabilizes IκBα pools through a downstream mechanism.
Immunofluorescence analysis revealed that KPV abolished TNF-α–evoked nuclear import of p65/RelA. Competition binding assays demonstrated a direct interaction between KPV and the Imp-α3 binding site on p65/RelA, specifically involving blockade of the importin-α armadillo domains 7 and 8. Pepsite binding analysis of KPV interaction with the closely related isoform Imp-α2 confirmed multiple possible interactions involving two or more KPV residues with amino acids 360–403, spanning armadillo repeat arms 7 and 8 (Land, 2012). This competitive inhibition of the nuclear localization signal (NLS)–importin interface represents a mechanistically novel approach to NF-κB suppression that is independent of melanocortin receptors MC1R–MC5R.
Downstream Cytokine Suppression
By preventing p65/RelA nuclear translocation, KPV effectively attenuates transcription of the NF-κB–dependent pro-inflammatory gene cassette. In in vitro models, nanomolar concentrations of KPV reduce secretion of TNF-α, IL-1β, IL-6, and IL-8 from stimulated epithelial and immune cell lines (Dalmasso et al., 2008). The functional consequence is a broad dampening of the inflammatory response at the transcriptional level, without the immunosuppressive liabilities associated with global IKK or proteasome inhibition.
PepT1-Mediated Cellular Uptake: The SLC15A1 Transporter Axis
A defining feature of KPV pharmacology is its transport across epithelial membranes via the proton-coupled oligopeptide transporter PepT1 (SLC15A1). PepT1 normally mediates concentrative uptake of dietary di- and tripeptides in the small intestine, coupling substrate translocation to the inwardly directed transmembrane electrochemical proton gradient. Cryo-electron microscopy studies have resolved the molecular architecture of human PepT1 in multiple conformational states, revealing the structural basis for its remarkable substrate promiscuity (Killer et al., 2021).
Dalmasso et al. (2008) provided the foundational evidence that PepT1 transports KPV into intestinal epithelial cells and that the subsequent increase in intracellular KPV concentration decreases activation of both NF-κB and MAPK inflammatory signaling pathways, ultimately reducing IL-8 secretion. Crucially, PepT1 expression is upregulated in colonic epithelium during inflammatory states, creating a pathophysiologically relevant uptake mechanism: inflamed tissue exhibits enhanced capacity for KPV absorption even at low extracellular concentrations (Dalmasso et al., 2008).
This transporter-mediated mechanism has significant implications for research into targeted delivery, as KPV’s tripeptide structure makes it an ideal substrate for SLC15A1-dependent cellular entry—a property not shared by larger melanocortin peptides or full-length α-MSH.
KPV in Preclinical Inflammatory Models
Intestinal Inflammation and Colitis Models
Kannengiesser et al. (2008) evaluated KPV in murine models of inflammatory bowel disease using both dextran sodium sulfate (DSS)– and 2,4,6-trinitrobenzenesulfonic acid (TNBS)–induced colitis. Oral administration of KPV reduced loss of body weight, colonic myeloperoxidase (MPO) activity, and histological signs of inflammation, while markedly decreasing pro-inflammatory cytokine mRNA levels. These findings established that the NF-κB inhibitory activity observed in vitro translates to measurable anti-inflammatory efficacy in preclinical intestinal models.
This product is sold for research purposes only and is not intended for human or animal consumption.
Airway Epithelial Cell Models
In human bronchial epithelial cells (16HBE14o- cell line), KPV suppressed both TNF-α– and LPS-induced NF-κB activation at concentrations as low as 10-9 M. The compound also reduced IL-8 secretion and suppressed systemic inflammation cues including COX-2 and ICAM-1 expression (Land, 2012). These data extend the anti-inflammatory profile of KPV beyond the gastrointestinal tract to respiratory epithelial surfaces, broadening the scope of potential research applications.
Keratinocyte and Dermal Models
Elliott et al. (2004) demonstrated that KPV activates signaling pathways in human keratinocytes, suggesting a direct mechanism for modulating cutaneous inflammatory responses. More recently, Sung et al. (2025) investigated KPV’s protective effects against fine particulate matter (PM10)–induced damage in HaCaT keratinocytes. Treatment with KPV restored cell viability, reduced IL-1β secretion, and inhibited reactive oxygen species (ROS) production. Mechanistically, KPV attenuated activation of the ERK/p38 MAPK axis and suppressed NF-κB–dependent expression of apoptosis-related proteins (Bax, Bcl-2, cleaved caspase-3), demonstrating dual anti-inflammatory and anti-apoptotic activity in cutaneous cell models.
Advanced Delivery Platforms: Nanoparticle and Hydrogel Systems
Hyaluronic Acid–Functionalized Nanoparticles
Xiao et al. (2017) developed hyaluronic acid (HA)–functionalized polymeric nanoparticles for targeted oral delivery of KPV. The HA-KPV nanoparticles (approximately 272 nm diameter, zeta potential of −5.3 mV) successfully mediated targeted delivery to colonic epithelial cells and macrophages. A critical finding was that HA-KPV nanoparticles achieved therapeutic efficacy at a dose 1,200-fold lower than free KPV in solution, underscoring the potential of nanoparticle-mediated delivery to enhance peptide bioavailability at inflammatory sites.
PepT1-Targeted Co-Assembly Nanodrugs
Zhang et al. (2024) reported a PepT1-targeted nanodrug platform based on co-assembly of KPV with the immunosuppressant FK506 (tacrolimus). These nanoparticles accumulated selectively in diseased intestinal regions by recognizing aberrantly expressed PepT1. In DSS-induced colitis models, treatment reduced oxidative stress markers (MPO, NO, ROS) and pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), while enhancing epithelial barrier integrity through upregulation of Mucin-2, ZO-1, and Claudin-5 expression.
Mucoadhesive Hydrogel Systems
Shao et al. (2021) developed an in situ mucoadhesive hydrogel capturing KPV (KPV@PPP_E) for application in oral mucosal models. The hydrogel formulation demonstrated anti-inflammatory, antibacterial, and tissue-repairing properties, significantly inhibiting IL-1β and TNF-α while upregulating IL-10. Notably, the KPV-loaded hydrogel exhibited antibacterial activity against MRSA-infected gingival ulcer wounds, indicating that KPV’s anti-inflammatory mechanism may synergize with antimicrobial tissue environments.
Self-Immolative Conjugates for Inflammation-Targeted Release
Cheng et al. (2026) introduced a self-immolative peptide prodrug conjugate (SIPPC) platform for oral delivery of anti-inflammatory peptides including KPV. The ROS-responsive conjugate (proKPV) achieved 3.8-fold greater colonic accumulation than free KPV, with enhanced efficacy at a 20-fold lower dose in colitis models. This inflammation-triggered release strategy represents the current frontier in KPV delivery research.
Combination Nanoparticle Platforms
Marotti et al. (2023) developed hybrid lipid nanoparticles functionalized with hyaluronan-KPV conjugates and loaded with teduglutide, creating a combined mucosal healing and immunomodulation platform. This triple-action system promoted endogenous GLP-2 production, provided targeted anti-inflammatory action via CD44/TLR4 pathway modulation, and enabled redox-responsive release of KPV through disulfide bond cleavage.
Melanocortin Receptor Selectivity and Structure-Activity Relationships
While KPV’s anti-inflammatory mechanism operates independently of classical melanocortin receptor activation, recent structure-activity studies have revealed that the –KPV motif plays a pivotal role in modulating melanotropin receptor selectivity. Nyberg et al. (2025) systematically examined the impact of the C-terminal –Lys-Pro-Val sequence on melanotropin conformation and receptor binding, demonstrating that incorporation of the –KPV motif enhanced binding affinity toward melanocortin receptors and modulated receptor preference among the MC1R–MC5R subtypes. These findings provide a structural framework for understanding how the same tripeptide sequence can mediate both receptor-dependent and receptor-independent biological activities—a dual functionality that distinguishes KPV from other melanocortin fragments and positions it as a versatile research tool in peptide pharmacology.
Researchers investigating related melanocortin peptides may find these structure-activity relationships informative for comparative studies. Additional peptides with complementary anti-inflammatory profiles, such as BPC-157 and Thymosin Alpha 1, have also been subjects of active investigation in NF-κB–related signaling research. All peptide research materials used in published studies should be accompanied by verified certificates of analysis.
Frequently Asked Questions
What is KPV and how does it relate to alpha-MSH?
KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment corresponding to positions 11–13 of alpha-melanocyte-stimulating hormone (α-MSH). Despite comprising only three amino acids with a molecular weight of approximately 342 Da, KPV retains significant anti-inflammatory activity from the parent hormone. Importantly, research demonstrates that KPV’s anti-inflammatory mechanism operates independently of classical melanocortin receptor (MC1R–MC5R) activation, distinguishing it from the full-length α-MSH peptide (Getting et al., 2003; Luger et al., 2003).
How does KPV inhibit the NF-κB signaling pathway?
KPV inhibits NF-κB through competitive blockade of p65/RelA nuclear import. Rather than preventing upstream IκBα phosphorylation, KPV enters the nucleus and competes with p65/RelA for binding to importin-α3 (Imp-α3), specifically at armadillo repeat domains 7 and 8. This prevents nuclear translocation of p65/RelA, thereby suppressing transcription of NF-κB–dependent pro-inflammatory genes including TNF-α, IL-1β, IL-6, and IL-8 (Land, 2012).
What role does PepT1 play in KPV uptake?
PepT1 (SLC15A1) is a proton-coupled oligopeptide transporter that mediates the active cellular uptake of KPV. As a tripeptide, KPV is an optimal substrate for PepT1-mediated transport. PepT1 expression is upregulated during intestinal inflammation, which increases the capacity for KPV absorption in inflamed tissue even at low concentrations. This transporter-mediated mechanism has been leveraged in the design of PepT1-targeted nanoparticle delivery systems (Dalmasso et al., 2008; Zhang et al., 2024).
What cytokines does KPV suppress in cell culture experiments?
In cell culture systems, nanomolar concentrations of KPV have been shown to suppress secretion of TNF-α, IL-1β, IL-6, and IL-8 from stimulated epithelial and immune cells. KPV also reduces expression of COX-2 and ICAM-1 in bronchial epithelial cell models, and attenuates ROS-dependent activation of ERK and p38 MAPK pathways in keratinocyte cultures (Land, 2012; Sung et al., 2025).
How do nanoparticle delivery systems enhance KPV activity?
Hyaluronic acid–functionalized nanoparticles have demonstrated the ability to deliver KPV at effective concentrations 1,200-fold lower than free KPV in solution. More recent self-immolative conjugate systems achieve 3.8-fold greater colonic tissue accumulation through ROS-responsive release mechanisms that are triggered specifically at sites of inflammation. PepT1-targeted co-assembly nanoparticles additionally exploit the upregulated transporter expression in inflamed tissue for enhanced selectivity (Xiao et al., 2017; Cheng et al., 2026).
Does KPV interact with melanocortin receptors?
Structure-activity relationship studies show that the –KPV motif modulates melanotropin receptor selectivity and enhances binding affinity toward melanocortin receptors when incorporated into larger peptide constructs. However, KPV’s anti-inflammatory activity in isolation appears to be primarily mediated through direct NF-κB pathway inhibition rather than classical melanocortin receptor signaling, representing a receptor-independent mechanism (Getting et al., 2003; Nyberg et al., 2025).
What are the most widely studied delivery platforms for KPV research?
Current KPV delivery research encompasses four major platform categories: (1) hyaluronic acid–functionalized polymeric nanoparticles for targeted colonic delivery; (2) PepT1-targeted co-assembly nanodrugs combining KPV with immunosuppressants; (3) mucoadhesive hydrogel systems for topical mucosal application; and (4) inflammation-triggered self-immolative prodrug conjugates for site-specific release. Each platform exploits different aspects of KPV’s physicochemical properties and the pathophysiology of inflammatory tissue environments.
All products referenced in this article are intended for laboratory research purposes only and are not for human or animal use. Researchers should consult institutional review protocols and applicable regulations before initiating any experimental procedures.
References
2 Day FAST Shipping
99%+ Purity Tests
Ships from Gilbert Arizona
USA Lab Tested
Free bacteriostatic water with every order.
Related Posts
GHRH Peptide: Anti-Aging & Sleep Benefits
Discover how GHRH uses gentle pulses to stimulate your pituitary gland, enhancing anti-aging benefits and supporting deep, restorative sleep. By optimizing your body composition and promoting natural cellular repair, GHRH could be your key to feeling youthful and energized every day.
Can I Buy Peptides Over the Counter?
If you’re curious about buying peptides without a prescription, you’re not alone. The peptide market has exploded in recent years, and understanding what’s legal, what’s safe, and what’s actually available over the counter can be confusing. Here’s the straight answer: Some peptides are available over the counter, but they’re limited to specific types. According to …
AI Peptides : Drug Discovery Solutions
Explore AI peptides and how artificial intelligence is revolutionizing drug discovery. Learn about the best solutions in peptide research and development.